CV protection in the EMPA-REG OUTCOME trial: A thrifty substrate hypothesis

Diabetes Care

Volumn 39, Issue 7, 2016, Pages 1108-1114

  Ferrannini, Ele ^a   Mark, Michael ^b   Mayoux, Eric ^b  

^a INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; DIURETIC AGENT; EMPAGLIFLOZIN; EPLERENONE; FATTY ACID; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; PLACEBO; SAXAGLIPTIN; TOFOGLIFLOZIN; URIC ACID; 3 HYDROXYBUTYRIC ACID; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSE BLOOD LEVEL; GLUCOSIDE; SLC5A2 PROTEIN, HUMAN; SODIUM GLUCOSE COTRANSPORTER 2;

BODY WEIGHT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CONFERENCE PAPER; DEPRESSED BLOOD PRESSURE; FATTY ACID OXIDATION; GLYCEMIC CONTROL; HEART DEATH; HEART FAILURE; HEART PROTECTION; HEMOCONCENTRATION; HOSPITALIZATION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXYGEN CONSUMPTION; PHASE 3 CLINICAL TRIAL (TOPIC); RISK REDUCTION; SYSTOLIC HEART FAILURE; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; BLOOD; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HEART; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; TREATMENT OUTCOME;

3-HYDROXYBUTYRIC ACID; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; GLUCOSIDES; HEART; HUMANS; HYPOGLYCEMIC AGENTS; MODELS, BIOLOGICAL; RESEARCH DESIGN; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84975853831     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc16-0330     Document Type: Conference Paper

References (75)

1. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovasculare disease in type 2 diabetes. Eur Heart J 2015;36:2288-2296
2. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
3. Fitchett D, Zinman B, Wanner C, et al.; EMPA-REG OUTCOME trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial. Eur Heart J. 26 January 2016 [Epub ahead of print]. DOI: 10.1093/eurheartj/ehv728
4. McMurray JJ, Adamopoulos S, Anker SD, et al.; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14: 803-869
5. Ryden L, Grant PJ, Anker SD, et al.; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035-3087
6. Inzucchi SE, Zinman B, Wanner C, et al. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res 2015;12:90-100
7. Muskiet MHA, van Raalte DH, van Bommel E, Smits MM, Tonneijck L Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 2015;3:928-929
8. Ceriello A, Genovese S, Mannucci E, Gronda E. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 2015;3:929-930
9. Gilbert RE, Connelly KA. Understanding EMPA-REG OUTCOME. Lancet Diabetes Endocrinol 2015;3:930-931
10. DeFronzo RA. The EMPA-REG study: what has it told us? A diabetologist's perspective. J Diabetes Complications 2016;30:1-2
11. McMurray J. EMPA-REG-the "diuretic hypothesis". J Diabetes Complications 2016; 30:3-4
12. Turnbull FM, Abraira C, Anderson RJ, et al.; Control Group. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Di-abetologia 2009;52:2288-2298
13. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009;85: 513-519
14. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597
15. Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA 2015;313:603-615
16. Psaty BM, Lumley T, Furberg CD, et al. Health outcomes associated with various anti-hypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534-2544
17. Olde Engberink RH, Frenkel WJ, van den Bogaard B, Brewster LM, Vogt L, van den Born BJ. Effects of thiazide-type and thiazide-like diuretics on cardiovascular events and mortality: systematic review and meta-analysis. Hypertension 2015;65:1033-1040
18. Zannad F, McMurray JJ, Krum H, et al.; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21
19. Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab 2013; 15:853-862
20. Roush GC, Kaur R, Ernst ME. Diuretics: a review and update. J Cardiovasc Pharmacol Ther 2014;19:5-13
21. Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, Pelleymounter MA. Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 2012;20:1645-1652
22. Yokono M, Takasu T, Hayashizaki Y, et al. SGLT2 selective inhibitor ipragliflozin reduces body fat mass by increasing fatty acid oxidation in high-fat diet-induced obese rats. Eur J Pharmacol 2014;727:66-74
23. Suzuki M, Takeda M, Kito A, et al. Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. Nutr Diabetes 2014;4:e125
24. Ferrannini E, Muscelli E, Frascerra S, et al. Metabolic response to sodium-glucose cotrans-porter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508
25. McGarry JD, Foster DW. Regulation of hepatic fatty acid oxidation and ketone body production. Annu Rev Biochem 1980;49:395-420
26. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr 2006;26:1-22
27. Ferrannini E, Baldi S, Frascerra S, et al. Shift to fatty substrates utilization in response to sodium-glucose co-transporter-2 inhibition in nondiabetic subjects and type 2 diabetic patients. Diabetes. 9 February 2016 [Epub ahead of print]. DOI: 10.2337/db15-1356
28. Nishimura R, Tanaka Y, Koiwai K, et al. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study. Cardiovasc Diabetol 2015;14:11
29. Nishimura R, Osonoi T, Kanada S, et al. Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study. Diabetes Obes Metab 2015; 17:800-804
30. Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y. The sodium-glucose co-transporter 2 inhibitor luseogliflozin improves glycaemic control assessed by continuous glucose monitoring even on a low-carbohydrate diet. Diabetes Obes Metab. 6 December 2015 [Epub ahead of print]. DOI: 10.1111/dom.12611
31. Ikeda S, Takano Y, Cynshi O, et al. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2015;17:984-993
32. Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H. Efficacy and safety of cana-gliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, phase III study. Expert Opin Pharmacother 2014;15:1501-1515
33. Balasse EO, Féry F. Ketone body production and disposal: effects of fasting, diabetes, and exercise. Diabetes Metab Rev 1989;5:247-270
34. Natali A, Buzzigoli G, Taddei S, et al. Effects of insulin on hemodynamics and metabolism in human forearm. Diabetes 1990;39:490-500
35. Bratusch-Marrain PR, DeFronzo RA. Failure of hyperketonemia to alter basal and insulin-mediated glucose metabolism in man. Horm Metab Res 1986;18:185-189
36. Ferrannini E, Santoro D, Bonadonna R, Natali A, Parodi O, Camici PG. Metabolic and hemodynamic effects of insulin on human hearts. Am J Physiol 1993;264:E308-E315
37. Camici PG, Marraccini P, Lorenzoni R, et al. Coronary hemodynamics and myocardial metabolism in patients with syndrome X: response to pacing stress. J Am Coll Cardiol 1991;17: 1461-1470
38. Garland PB, Newsholme EA, Randle PJ. Regulation of glucose uptake by muscle. 9. Effects of fatty acids and ketone bodies, and of alloxan-diabetes and starvation, on pyruvate metabolism and on lactate-pyruvate and L-glycerol 3-phosphate-dihydroxyacetone phosphate concentration ratios in rat heart and rat diaphragm muscles. Biochem J 1964;93:665-678
39. Kashiwaya Y, King MT, Veech RL. Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart. Am J Cardiol 1997;80:50A-64A
40. Stanley WC, Meadows SR, Kivilo KM, Roth BA, Lopaschuk GD. b-Hydroxybutyrate inhibits myocardial fatty acid oxidation in vivo independent of changes in malonyl-CoA content. Am J Physiol Heart Circ Physiol 2003;285:H1626-H1631
41. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone bodies, and mitochondrial energy trans-duction. FASEB J 1995;9:651-658
42. Boveris A, Oshino N, Chance B. The cellular production of hydrogen peroxide. Biochem J 1972;128:617-630
43. Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009;417: 1-13
44. Shimazu T, Hirschey MD, Newman J, et al. Suppression of oxidative stress by b-hydroxybu-tyrate, an endogenous histone deacetylase inhibitor. Science 2013;339:211-214
45. Cotter DG, Schugar RC, Crawford PA. Ke-tone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 2013;304: H1060-H1076
46. Iozzo P, Chareonthaitawee P, Dutka D, Betteridge DJ, Ferrannini E, Camici PG. Independent association of type 2 diabetes and coronary artery disease with myocardial insulin resistance. Diabetes 2002;51:3020-3024
47. Paternostro G, Camici PG, Lammerstma AA, et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 1996;98:2094-2099
48. Camici P, Marraccini P, Lorenzoni R, et al. Metabolic markers of stress-induced myocardi-al ischemia. Circulation 1991;83(Suppl.):III8-III13
49. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32:217-238
50. Lopaschuk GD, Ussher JR, Folmes CDL, Jaswal JS, Stanley WC. Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207-258
51. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129
52. Neubauer S. The failing heartdan engine out of fuel. N Engl J Med 2007;356:1140-1151
53. Chouchani ET, Pell VR, Gaude E, et al. Is-chaemic accumulation of succinate controls re-perfusion injury through mitochondrial ROS. Nature 2014;515:431-435
54. Tanaka M, Nishigaki Y, Fuku N, Ibi T, Sahashi K, Koga Y. Therapeutic potential of pyruvate therapy for mitochondrial diseases. Mitochondrion 2007;7:399-401
55. Fujii T, Nozaki F, Saito K, et al. Efficacy of pyruvate therapy in patients with mitochondrial disease: a semi-quantitative clinical evaluation study. Mol Genet Metab 2014;112:133-138
56. Aubert G, Martin OJ, Horton JL, et al. The failing heart relies on ketone bodies as a fuel. Circulation 2016;133:698-705
57. Janardhan A, Chen J, Crawford PA. Altered systemic ketone body metabolism in advanced heart failure. Tex Heart Inst J 2011;38:533-538
58. Bedi KC Jr, Snyder NW, Brandimarto J, et al. Evidence for intramyocardial disruption of lipid metabolism and myocardial ketone utilization in advanced human heart failure. Circulation 2016;133:706-716
59. 1H-NMR-based metabolic analysis of human serum reveals novel markers of myocardial energy expenditure in heart failure patients. PLoS One 2014; 9:e88102
60. Kolwicz SC Jr, Airhart S, Tian R. Ketones step to the plate: a game changer for metabolic remodeling in heart failure? Circulation 2016;133: 689-691
61. Mudaliar S, Polidori D, Zambrowicz B, Henry RR. Sodium-glucose cotransporter inhibitors: effects on renal and intestinal glucose transport: from bench to bedside. Diabetes Care 2015;38:2344-2353
62. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion during the treatment of decom-pensated heart failure on renal function and survival. Circulation 2010;122:265-272
63. McBride BF, White CM. Anemia management in heart failure: a thick review of thin data. Pharmacotherapy 2004;24:757-767
64. Martini J, Tsai AG, Cabrales P, Johnson PC, Intaglietta M. Increased cardiac output and mi-crovascular blood flow during mild hemocon-centration in hamster window model. Am J Physiol Heart Circ Physiol 2006;291:H310-H317
65. Mentz RJ, O'Connor CM. Pathophysiology and clinical evaluation of acute heart failure. Nat Rev Cardiol 2016;13:28-35
66. Greene SJ, Gheorghiade M, Vaduganathan M, et al.; EVEREST Trial investigators. Haemo-concentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 2013;15: 1401-1411
67. van der Meer P, Postmus D, Ponikowski P, et al. Thepredictive value ofshort-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure. J Am Coll Cardiol 2013;61:1973-1981
68. Cahill GF Jr, Veech RL. Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003; 114:149-161
69. Veech RL. The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochon-drial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004;70:309-319
70. Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr. Ketone bodies, potential therapeutic uses. IUBMB Life 2001;51:241-247
71. Astrup A, Meinert Larsen T, Harper A. Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? Lancet 2004; 364:897-899
72. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 2015;38:1638-1642
73. Doehner W, Frenneaux M, Anker SD. Metabolic impairment in heart failure: the myocar-dial and systemic perspective. J Am Coll Cardiol 2014;64:1388-1400
74. Doehner W, Rauchhaus M, Ponikowski P, et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-1026
75. Iozzo P, Chareonthaitawee P, Rimoldi O, Betteridge DJ, Camici PG, Ferrannini E. Mismatch between insulin-mediated glucose uptake and blood flow in the heart of patients with type II diabetes. Diabetologia 2002;45:1404-1409